The Road to Opioid-Induced Constipation: Pathophysiology and Impact Kenneth C. Jackson, II, PharmD, CPE
|
|
- Peregrine Marsh
- 5 years ago
- Views:
Transcription
1
2 Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of March The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Creative Educational Concepts or the supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
3 Usage Rights This slide deck is provided for educational purposes and slides may be used for personal, non-commercial presentations only as long as content and references remain the same. No part of this slide deck may be published or distributed in print or electronic format without prior written permission from Creative Educational Concepts.
4 The Road to Opioid-Induced Constipation: Pathophysiology and Impact Kenneth C. Jackson, II, PharmD, CPE Professor and Chair Department of Clinical and Administrative Sciences Larkin Health Sciences Institute College of Pharmacy Miami, FL
5 Pain is a Problem! Condition Incidence Source Chronic Pain Diabetes Coronary Heart Disease (heart attack and chest pain) Stroke 100 million Americans 25.8 million Americans (diagnosed and estimated undiagnosed) 16.3 million Americans 7.0 million Americans Institute of Medicine of The National Academies American Diabetes Association American Heart Association Cancer 11.9 million Americans American Cancer Society
6 Chronic Pain 22% of primary care visits focus on pain Chronic pain patients visit primary care providers up to 5 times more often than patients with other chronic conditions Cost to United States (US) healthcare is $ billion/year Lost productivity estimated $ billion/year Opioids accounted for 20% of overall drug cost $3.57 billion/year between Rasu RS, et al. J Manag Care Pharm
7 mg/capita US Opioid Consumption in mg/capita ME mg/capita Fentanyl Hydromorphone Methadone Morphine Oxycodone Meperidine ME=Morphine Equivalent Total Morphine Equivalence=
8 Opioid-Induced Adverse Effects Constipation Nausea/vomiting Sedation Pruritus Respiratory depression Androgen deficiency Psychotomimetic effects Hyperalgesia
9 Opioid-Induced Constipation (OIC) Pathophysiology The enteric nervous system is innervated by μ-, δ-, and κ-opiate receptors (MOR, DOR, and KOR) Opioid receptor agonists interact with these receptors Inhibit adenylate cyclase Decrease camp and PKA Activate K + channels Membrane hyperpolarization Inhibit Ca ++ channels Decrease neurotransmitter release Galligan JJ, et al. Am J Gastroenterol Suppl
10 OIC Mechanisms Increased ileocecal and anal sphincter tone Decreased defecation reflexes Decreased peristalsis and increased gastrointestinal (GI) tone Increased fluid absorption due to increased contact time Decreased enterocyte secretion Smith H, et al. Opioid Therapy in the 21 st Century
11 Constipation Defined: American College of Gastroenterology Unsatisfactory defecation characterized by: Infrequent stools Difficult stool passage Straining Sense of difficult stool passage Incomplete evacuation Hard lumpy stools Prolonged time to stool Need for manual maneuvers to pass stool Or infrequent stools and difficult stool passage Ford AD, et al. Am J Gastroenterol
12 Rome III Criteria: Functional Constipation Must include two or more of the following: Straining during at least 25% of defecations Lumpy or hard stools in at least 25% of defecations Sensation of incomplete evacuation for at least 25% of defecations Sensation of anorectal obstruction/blockage for at least 25% of defecations Manual maneuvers to facilitate at least 25% of defecations (eg, digital evacuation, support of the pelvic floor) Fewer than three defecations per week Loose stools are rarely present without the use of laxatives Insufficient criteria for irritable bowel syndrome
13 What is OIC? Also known as: Opioid Bowel Dysfunction (OBD) and Opioid-Induced Bowel Dysfunction (OIBD) Characterized by: Hard, dry stools Straining to pass bowel movements Incomplete evacuation Bloating Abdominal distension Increased gastric reflux Bell TJ, et al. Pain Med
14 Bristol Stool Chart Constipation Diarrhea
15 Proposed Definition-OIC A change, when initiating opioid therapy, from baseline bowel habits, defecation patterns, and what individuals would consider as abnormal that is characterized by any of the following: Reduced frequency of spontaneous (in contrast to induced) bowel movements Development or worsening of straining to pass bowel movements A sense of incomplete rectal evacuation Harder stool consistency Gaertner J, et al. J Clin Gastroenterol
16 Incidence of OIC Acute Pain Hard to evaluate! Chronic Non-Cancer Pain (CNCP) Often cited as the most common and debilitating adverse effect Estimates of the frequency of constipation vary from 15-90% in patients receiving opioids for non-cancer pain Variation may be due to definition of opioid agent/type and actual frequency of use Abdominal pain as high as 58.2% Cancer Pain up to 90% Panchal SJ, et al. Int J Clin Pract. 2007; Thomas J. J Pain Symptom Manage. 2008; Dorn S, et al. Am J Gastroenterol Suppl
17 OIC in Chronic Non-Cancer Pain PROBE 1 The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey Survey of 322 patients with CNCP Daily use of opioids AND laxatives 45% of patients reported <3 bowel movements per week Constipation (81%) Straining to pass a bowel movement (58%) Rank order of most bothersome adverse effects by patients Constipation, straining, fatigue, small or hard bowel movements, and insomnia A third of patients had missed, decreased, or stopped using opioids in order to make it easier to have a bowel movement Bell TJ, et al. Pain Med
18 Chronic Pain Treatment Paradigm Physical Back exercises Aerobic exercise Behavioral Stress management Mental Health Pharmacotherapy
19 Physician and Nurse Perceptions of Most Difficult Symptoms in Palliative Care Primary Care Physicians Loss of appetite 49% Lost bowel control 43% Unpleasant smell 40% Lost bladder control 35% Breathlessness 35% Bedsores 34% Depression 31% Home Care Nurses Loss of appetite 54% Depression 54% Anxiety 51% Nausea/vomiting 37% Constipation 32% Breathlessness 31% Sleeplessness 30% Pain 26% Grande GE, et al. Palliative Medicine
20 Opioids: Ceiling Effect The dose at which further dose increases will not produce additional analgesia. Full agonists - no true ceiling effect Doses can be escalated as appropriate to treat pain Functional dose ceiling Adverse effects >>> Analgesia Example: Codeine in doses > mg produce significant GI effects that exceed any potential, incremental pain Partial and mixed agonist/antagonists exhibit ceiling effect Jackson KC, et al. Practical Pain Management. 3 rd Edition
21 Distinct Types of Opioid Tolerance Analgesia May occur in first days to weeks of therapy Rare after pain relief achieved with consistent dosing without increasing or new pathology Respiratory depression and sedation Predictable after 5-7 days of consistent opioid administration Constipation Tolerance does not occur Prophylactic treatment indicated with regularly scheduled opioids Jackson KC, et al. Practical Pain Management. 3 rd Edition
22 Potential Etiologies of Opioid-Associated Constipation Normal-transit constipation Slow-transit constipation Evacuation disorders Secondary causes of constipation: Medications Medical Conditions Malignancy, neurological disorders, metabolic disorders, endocrine disorders, myopathic disorders Mechanical obstruction Pregnancy Brenner DM, et al. Am J Gastroenterol Suppl
23 Monitoring Opioid Therapy Critical Outcomes Pain relief Function Physical Psychosocial Side effects Drug-related behaviors The 4-A's of Pain 1. Analgesia 2. Activities of daily living 3. Adverse effects 4. Aberrant drug-taking behaviors Passik SD, et al. Adv Ther
24 Starting the Journey and Staying the Course: Education, Prevention and First Line Treatment Leah Sera, PharmD, BCPS Assistant Professor Department of Pharmacy Practice and Science University of Maryland School of Pharmacy Baltimore, MD
25 Who s at Risk? Patients Taking Certain Medications Calcium channel blockers Antidepressants Antihistamines Metal ion containing agents Antipsychotics Antiepileptics Antiemetics Patients with Certain Medical Conditions Diabetes Parkinson s disease Pregnancy Hypothyroidism Multiple sclerosis Electrolyte imbalance Costilla VC, et al. Clin Geriatr Med
26 Who s at Risk? Functional Factors Poor appetite/food intake Low fiber diet Poor fluid intake Advanced age Inactivity/decreased mobility Depression/sedation Environment Larkin PJ, et al. Pall Med
27 Preventive Care Lifestyle modifications as needed Adequate hydration (especially fruit/fruit juice) Increase dietary fiber Increasing physical activity Access to laxatives if needed Patients taking opioids should use laxatives prophylactically Maintaining good bowel habits Don t suppress the urge to defecate Make sure patient has adequate privacy and assistance with toileting if needed
28 Assessing Constipation Ask about past and present bowel habits Ask about use of laxatives Ask about date of the most recent bowel movement Ask about associated symptoms Nausea/vomiting, abdominal pain, diarrhea Twycross R, et al. J Pain Symptom Manage
29 Bowel Function Index 3-question patient assessment scale On a scale of 0 (not at all) (very strong), over the last 7 days Ease of defecation Feeling of incomplete bowel evacuation Personal judgment of constipation Higher scores indicate greater constipation Ducrotté P, et al. Curr Med Res Opin
30 Triage and Red Flags Patient should contact a healthcare clinician if: No bowel movement in 4 days New or worsening constipation despite lifestyle modifications or OTC laxative use Alternating diarrhea and constipation New or worsening abdominal pain Bloody stools Unintended weight loss Schisler RE, et al. J Palliat Med. 2012; Kumar L, et al. Gastroenterol Res Pract
31 Stimulant Laxatives Examples: Sennosides and bisacodyl Mechanism of Action Stimulate peristalsis directly by acting on intestinal smooth muscle Increases fecal water content by altering intestinal fluid and electrolyte secretion Contraindications Intestinal obstruction Acute or undiagnosed abdominal pain Adverse Effects Diarrhea Intestinal colic Rectal irritation (with rectal administration) Twycross R, et al. J Pain Symptom Manage
32 Osmotic Laxatives Examples: Polyethylene glycol, lactulose, and magnesium salts Mechanism of Action Draws water into the intestinal lumen Softens stool and causes bowel distention and stimulation of peristalsis Contraindications Caution in patients with renal impairment (Mg ++ salts) Adverse Effects GI upset (bloating and gas particularly with lactulose) Electrolyte imbalance Liu LW. Can J Gastroenterol
33 Docusate Mechanism of Action Lowers surface tension, allowing water and fat to penetrate and soften stool Contraindications Acute or undiagnosed abdominal pain Adverse Effects Generally well tolerated May see mild cramping and diarrhea Twycross R, et al. J Pain Symptom Manage
34 Mean Number of BMs Senna + Docusate: A Dynamic Duo? Docusate + Sennosides vs. Placebo + Sennosides Randomized, double-blind, placebo-controlled trial, N=74 No significant between-group differences in stool frequency, volume, or consistency; or difficulty or completeness of evacuation Study Day Docusate Placebo BM=Bowel movement Tarumi Y, et al. J Pain Symptom Manage
35 Bulk Forming Laxatives Examples: Psyllium, methylcellulose Mechanism of Action Increases fecal bulk, distends colon, and stimulates peristalsis NOT Recommended in OIC Opioids prevent peristalsis of fiber-increased bulk Can cause abdominal pain and lead to bowel obstruction Galligan JJ, et al. Gastroenterol Res Pract
36 Example Bowel Protocol Goal: Achieve a bowel movement every 1-3 days without straining (if more than 3 days since last bowel movement consider suppositories/enema) Start with senna 17.2 mg at bedtime Increase senna dose every hours as needed to maximum dose of 34.4 mg 3 times a day If no result at maximum tolerated dose, half senna dose and add osmotic laxative (eg, lactulose or polyethylene glycol) Twycross R, et al. J Pain Symptom Manage
37 Wrong Turn! Developing a New Plan James B. Ray, PharmD, CPE Pharmacy Clinical Coordinator Pain and Palliative Care University of Virginia Health System Charlottesville, VA Clinical Assistant Professor Virginia Commonwealth University School of Pharmacy Richmond, VA
38 Action of Opioids and PAMORAs in the CNS and GI Tract Becker G, et al. Lancet
39 Alvimopan First in PAMORA class Indicated for GI recovery following surgery Studied in OIC Improved SBMs at three dose levels compared to placebo over 6 weeks Cardiovascular risk signal Boxed warning Risk Evaluation Mitigation Strategies (REMS) program SBM=Spontaneous bowel movement Webster L, et al. Pain
40 Cardiovascular Risk June 2014 FDA advisory committee votes to not require cardiovascular outcome trials Post-approval data collection for cardiovascular safety /Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM pdf.
41 Methylnaltrexone Bromide Indications Patients with advanced illness not responding to laxatives (palliative care) OIC in adult patients with CNCP Formulations Subcutaneous injection, investigational oral form Thomas J, et al. N Engl J Med
42 Patients with Laxation Response (%) Methylnaltrexone Bromide in Advanced Illness Placebo (N=71) 15 48* Laxation within 4 Hr after the First Dose Methylnaltrexone (N=62) 8 52* Laxation within 4 Hr after 2 of the First 4 Doses No evidence of opioid withdrawal observed Abdominal pain & flatulence most common adverse events *P<.001 for both Thomas J, et al. N Engl J Med
43 Methylnaltrexone Bromide in CNCP 4-week Randomized Controlled Trial (RCT) of subcutaneous injection (12 mg daily or every other day) 28.9% of methylnaltrexone subcutaneous daily and 30.2% of methylnaltrexone subcutaneous every other day resulted in rescue-free bowel movements (RFBMs) within 4 hr compared to 9.4% daily and 9.3% every other day with placebo 12-week RCT of oral (150 mg, 300 mg and 450 mg for 4 weeks daily, then 8 weeks as needed) Dose dependent increase in RFBM and decreased time to 1 st RFBM compared to placebo Michna E, et al. J Pain. 2011; Rauck RL, et al. Gastroenterol
44 Methylnaltrexone Bromide Dosing Common Adverse Events <38 kg 0.15 mg/kg kg 8 mg kg 12 mg >114 kg 0.15 mg/kg Abdominal pain, diarrhea, nausea, hyperhidrosis Contraindications Known or suspected mechanical gastrointestinal obstruction
45 Naloxegol PEGylated form of naloxone Reduces passive permeability across the blood-brain barrier Substrate of P-glycoprotein transporter Metabolism CYP3A4, weak inhibitor of CYP2D6 & CYP2C19 Enterohepatic recycling Daily dosing: 25 mg orally 1 hour prior or 2 hours after a meal Avoid grapefruit juice Leonard J, et al. Ann Pharmacother
46 Naloxegol Primary Endpoint: Response* Study 1 (KODIAC-04) Placebo (N=214) 12.5 mg (N=213) 25 mg (N=214) Patients responding 63 (29%) 87 (41%) 95 (44%) 95% CI (2.4%, 20.4%) (5.9%, 24%) P value Study 2 (KODIAC-05) Placebo (N=232) 12.5 mg (N=232) 25 mg (N=232) Patients responding 68 (29%) 81 (35%) 92 (40%) 95% CI (-2.9%, 14.1%) (1.7%, 18.9%) P value *12-week response rate ( 3 spontaneous bowel movements per week and an increase from baseline of 1 spontaneous bowel movements for 9 of 12 weeks and for 3 of the final 4 weeks) Chey WD, et al. N Engl J Med
47 Patients (%) Patients (%) * Naloxegol 44.4* * Relative Risk (95% CI) 1.38 ( ) 1.51 ( ) 1.19 ( ) 1.35 ( ) No. Needed to Treat N= N=214; P= * N=213; P=.001 N=232 N= * N=232; P= * Relative Risk (95% CI) 1.48 ( ) 1.69 ( ) 1.35 ( ) 1.49 ( ) No. Needed to Treat *Statistically significant KODIAC-04 KODIAC-04 N=118 N=115; P=.03 N=117; P=.002 KODIAC-05 KODIAC-05 N=121 N=125 N=124; P=.01 Placebo Naloxegol 12.5 mg Naloxegol 25 mg Intent to Treat Population Inadequate Response to Laxative Population Chey WD, et al. N Engl J Med
48 Naloxegol Adverse Reactions Adverse Reactions in Patients with OIC and CNCP Naloxegol 25 mg (N=446) Naloxegol 12.5 mg (N=441) Placebo (N=444) Abdominal Pain 20% 12% 7% Diarrhea 9% 6% 4% Nausea 8% 7% 5% Flatulence 6% 3% 3% Vomiting 5% 2% 3% Headache 5% 4% 3% Hyperhidrosis 3% <1% <1% Chey WD, et al. N Engl J Med
49 Naloxegol Cautions Patients with known or suspected GI obstruction and patients at increased risk of recurrent obstruction due to the potential for GI perforation Patients receiving strong CYP3A4 inhibitors which can significantly increase exposure to naloxegol which may precipitate opioid withdrawal symptoms Dose adjustment for CrCl <60 ml/min, not recommended in patients with severe hepatic impairment FDA Prescribing Information.
50 Lubiprostone Chloride channel activator (ClC-2) Promotes fluid secretion increased motility Bypasses the antisecretory action of opioids Indications Chronic Idiopathic Constipation (CIC) in adults Opioid-Induced Constipation (OIC) in adults with CNCP 24 mcg orally twice daily Irritable Bowel Syndrome with Constipation (IBS-C) in women 18 years old 8 mcg orally twice daily
51 Lubiprostone for OIC in CNCP Study 1 Study 2 Study 3 Trial Design RCT, double-blind, placebocontrolled, 12 week (excluded methadone) 1 RCT, double-blind, placebocontrolled, 12 week 2 RCT, double-blind, placebocontrolled, 12 week 3 Response Lubiprostone-26.9% (N=214) Placebo-18.6% (N=217) P= Lubiprostone-3.3 SBMs (N=210) Placebo-2.4 SBMs (N=208) P= Lubiprostone-2.7 SBMs (N=235) Placebo-2.5 SBMs (N=216) P= Jamal MM, et al. Gastroenterol. 2012; 2 Cryer B, et al. Pain Med. 2014; 3 Spierings EL, et al. Gastroenterol
52 Response Rate (%) Lubiprostone for OIC in CNCP 30 Overall SBM Responders* 26.9% P=.035 Median Time to First SBM Placebo % P= Lubiprostone Lubiprostone Placebo 0 20 Time (Hours) 40 RCT, double-blind, placebo-controlled, 12 week (excluded methadone), primary efficacy endpoint: overall SBM response rate *Defined as having 3 or more SBMs per week for at least 9 weeks, and at least 1 additional SBM over mean baseline Jamal MM, et al. Gastroenterol
53 Mean Change from Baseline in SBM Frequency Lubiprostone 4 P=.005 P=.091 Placebo (N=208) Lubiprostone (N=210) 3 P= Week 8 Week 12 Overall No. of Observations RCT, double-blind, placebo-controlled, 12 week Primary endpoint: change from baseline in SBM frequency at week 8 Cryer B, et al. Pain Med
54 Mean Score Mean Score Lubiprostone vs. Senna Gastrointestinal Outcomes: Patient Assessment in Constipation 1.5 PAC-SYM* Lubiprostone (N=28) Senna (N=28) PAC-QOL** Baseline Day 7 Baseline Day 7 There was no significant difference found between lubiprostone and senna in the change from baseline to day 7 for PAC-SYM (P=.89) or PAC-QOL (P=.30) *Higher numbers indicate more symptoms; **Higher numbers indicate better quality of life 0 Marciniak CM, et al. World J Gastroenterol
55 Lubiprostone Nausea most frequent adverse event Decreased when administered with food Cautions Reduce dose in moderate (16 mcg twice daily) to severe (8 mcg twice daily) hepatic impairment Development of diarrhea and dyspnea Methadone can inhibit lubiprostone s ability to activate CIC-2 channels in intestinal cells Pregnancy Category C Should not be used in women who are pregnant or trying to become pregnant FDA Prescribing Information.
56 The Horizon Investigational PAMORAs Axelopran (TD 1211) Bevenopran Naldemedine Other Agents Prucalopride (5-HT 4 agonist) Linaclotide Guanylate cyclase-c agonist
57
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES
OPIOID-INDUCED CONSTIPATION DR ANDREW DAVIES Introduction Introduction Mean faecal weight 128 g / cap / day Mean range 51-796 g Absolute range 15-1505 g Main factors affecting mass are caloric intake,
More informationOpioid-Induced Constipation
Objectives Opioid-Induced Constipation Brianna Jansma, PharmD Alex Smith, PharmD Megan Robinson, PharmD Summarize epidemiology of opioid-induced constipation (OIC) Understand opiates effects on the gastrointestinal
More informationdaily; available as 10- mg g PO
Overview of the PRN: The Pain and Palliative Care PRN of ACCP is an organization of pharmacy practitioners, clinical scientists, pharmacy educators, and others. Its mission is to advance pain and palliative
More informationSYMPROIC (naldemedine tosylate) oral capsule
SYMPROIC (naldemedine tosylate) oral capsule Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Symproic GENERIC NAME Naldemedine MANUFACTURER Shionogi Inc. DATE OF APPROVAL March 23, 2017 PRODUCT LAUNCH DATE Anticipated to launch mid-summer 2017 REVIEW TYPE Review type 1 (RT1): New Drug
More informationElderly Man With Chronic Constipation
Elderly Man With Chronic Constipation Linda Nguyen, MD Director, Neurogastroenterology and Motility Clinical Assistant Professor Stanford University Overview Normal bowel function Defining Constipation:
More informationConstipation an Old Friend. Presented by Dr. Keith Harris
Constipation an Old Friend Presented by Dr. Keith Harris Irregularity and the Tricks of the Trade." CONSTIPATION What is constipation? INFREQUENT BOWEL MOVEMENTS DIFFICULTY DURING DEFECATION SENSATION
More informationEfficacy and Safety of Lubiprostone. Laura Wozniak February 23, 2010 K30 Monthly Journal Club
Efficacy and Safety of Lubiprostone Laura Wozniak February 23, 2010 K30 Monthly Journal Club Objectives Brief overview of constipation Review of article Discussion Constipation in Children 3-5% of all
More informationOpioid Use in Palliative Care
Opioid Use in Palliative Care Relief of pain is one of the core components of palliative care 1,2 Up to 69% of patients with advanced cancer experience pain 3 ~65% of patients dying from nonmalignant disease
More informationConstipation An Overview. Definition Physiology of GI tract Etiology Assessment Treatment
CONSTIPATION Constipation An Overview Definition Physiology of GI tract Etiology Assessment Treatment Definition Constipation = the infrequent passage of hard feces Definition of Infrequent The meaning
More informationConstipation. What is constipation? What is the criteria for having constipation? What are the different types of constipation?
What is constipation? is defined as having a bowel movement less than 3 times per week. It is usually associated with hard stools or difficulty passing stools. You may have pain while passing stools or
More informationWhat Is Constipation?
CONSTIPATION What Is Constipation? Constipation is when you have infrequent or hard-to-pass bowel movements (meaning they are painful or you have to strain), have hard stools or feel like your bowel movements
More informationACTIVITY DESCRIPTION FACULTY. Opioid Use in Palliative Care. Opioid Analgesic Use in Chronic, Non-cancer Pain
ACTIVITY DESCRIPTION Target Audience This continuing pharmacy education activity is planned to meet the needs of pharmacists in a variety of practice settings, including large and small healthcare systems,
More informationAmitiza. Amitiza (lubiprostone) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.22 Subject: Amitiza Page: 1 of 5 Last Review Date: March 16, 2018 Amitiza Description Amitiza (lubiprostone)
More informationPharmacy Benefit Determination Policy
Policy Subject: Opioid Induced Constipation Policy Number: SHS PBD11 Category: GI Agents Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS
More informationUnderstanding & Alleviating Constipation. Living (Well!) with Gastroparesis Program Warm-Up Class
Understanding & Alleviating Constipation Living (Well!) with Gastroparesis Program Warm-Up Class Please Remember The information presented is for educational purposes only and is in no way intended as
More informationChronic constipation in the elderly
Chronic constipation in the elderly 1 Dec,2011 R 2 Natta Asanaleykha Epidemiology Definition Scope The impact of chronic constipation in the elderly Pathophysiology Evaluation the elderly patient with
More informationOral Methylnaltrexone for the. Constipation in Patients with Chronic Non-cancer Pain
Oral Methylnaltrexone for the Treatment of Opioid-induced Constipation in Patients with Chronic Non-cancer Pain Richard L. Rauck, 1 John F. Peppin, 2 Robert J.Israel, 3 Jennifer Carpenito, 3 Jeffrey Cohn,
More informationDrugs Affecting the Gastrointestinal System. Antidiarrheal and Laxatives
Drugs Affecting the Gastrointestinal System Antidiarrheal and Laxatives Diarrhea Abnormal frequent passage of loose stools or Abnormal passage of stools with increased frequency, fluidity, and weight,
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland
More informationFOOT OFF THE BRAKES. Kerri Novak MD MSc FRCPC. Chronic Constipation: Taking the Foot off the Brakes Dr. Kerri Novak
CHRONIC CONSTIPATION: TAKING THE FOOT OFF THE BRAKES Kerri Novak MD MSc FRCPC www.seacourses.com 1 OUTLINE Epidemiology i Quality of life Approach Therapies www.seacourses.com 2 DEFINING CHRONIC CONSTIPATION
More informationAntidiarrheals Antidiarrheal
Antidiarrheals Major factors in diarrhea Increased motility of the GI tract. Decreased absorption of fluid. Antidiarrheal drugs include: Antimotility agents. Adsorbents. Drugs that modify fluid and electrolyte
More informationIrritable Bowel Syndrome. Mustafa Giaffer March 2017
Irritable Bowel Syndrome Mustafa Giaffer March 2017 Introduction First described in 1771. 50% of patients present
More informationIdentify electrolytes that should be monitored whenever prolonged or severe diarrhea is present
Chapter 35 Drugs Used to Treat Constipation and Diarrhea Learning Objectives State the underlying causes of constipation Explain the meaning of normal bowel habits Cite nine causes of diarrhea Describe
More informationOpioid-Induced Constipation: Update on Prevention and Management EDUCATIONALPROGRAM
EDUCATIONALPROGRAM Recognizing i the Growing Burden of OIC Bill H. McCarberg, MD Founder, Chronic Pain Management Program Kaiser Permanente San Diego Adjunct Assistant Clinical Professor University of
More informationSUPPLEMENTARY INFORMATION Associated with
Table1: Rome III and Rome IV diagnostic criteria for IBS, functional constipation and functional dyspepsia. Rome III diagnostic criteria 1,2 Rome IV diagnostic criteria 3,4 Diagnostic criteria for IBS
More informationIrritable Bowel Syndrome Now. George M. Logan, MD Friday, May 5, :35 4:05 PM
Irritable Bowel Syndrome Now George M. Logan, MD Friday, May 5, 2017 3:35 4:05 PM Dr. Logan indicated no potential conflict of interest to this presentation. He does not intend to discuss any unapproved/investigative
More informationProtectives and Adsorbents. Inorganic chemistry Course 1 Third year Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry
Protectives and Adsorbents Inorganic chemistry Course 1 Third year 2016-2017 Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry Protectives and Adsorbents This group of gastrointestinal agents
More informationConstipation and bowel obstruction
Constipation and bowel obstruction Constipation Infrequent or difficult defecation with reduced number of bowel movements, which may or may not be abnormally hard with increased difficulty or discomfort
More informationDrugs in Development for Opioid-Induced Constipation
7 Drugs in Development for Opioid-Induced Constipation Kelly S. Sprawls, Egilius L.H. Spierings and Dustin Tran MedVadis Research Corporation USA 1. Introduction Opioid-induced bowel dysfunction (OIBD)
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationTechnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345
Naloxegol for treating opioid-induced constipation Technology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta345 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationIBS Irritable Bowel syndrome Therapeutics II PHCL 430
Salman Bin AbdulAziz University College Of Pharmacy IBS Irritable Bowel syndrome Therapeutics II PHCL 430 Email:- ahmedadel.pharmd@gmail.com Ahmed A AlAmer PharmD R.S is 32-year-old woman experiences intermittent
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 2Q17 April May
BRAND NAME Trulance GENERIC NAME Plecanatide MANUFACTURER Synergy Pharmaceuticals, Inc. DATE OF APPROVAL January 19, 2017 PRODUCT LAUNCH DATE Anticipated in 1Q2017 REVIEW TYPE Review type 1 (RT1): New
More information10/10/16. Disclosures. Educational Objectives
Nimish Vakil, MD, FACP, FACG, AGAF, FASGE Clinical Adjunct Professor University of Wisconsin Madison, Wisconsin Disclosures All faculty, course directors, planning committee, content reviewers and others
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationImproving the Diagnosis and Management of Opioid-induced Constipation to Optimize Outcomes of Patients with Chronic Pain
Improving the Diagnosis and Management of Opioid-induced Constipation to Optimize Outcomes of Patients with Chronic Pain Sponsored by Integrity Continuing Education, Inc. Supported by an educational grant
More informationPrimary Care Constipation Guidelines. Version 1 November 2016
Primary Care Constipation Guidelines Version 1 November 2016 VERSION CONTROL Version Date Amendments made Version 1 November 2016 New guideline Contents 1. Management of constipation in adults: acute and
More informationOpioids and the Gastroenterologist: A Painful Issue
Opioids and the Gastroenterologist: A Painful Issue Wendell K. Clarkston, MD Professor of Medicine GI Program Director UMKC School of Medicine Disclosures: No financial relationships to disclose 1 Outline
More informationIBS: overview and assessment of pain outcomes and implications for inclusion criteria
IBS: overview and assessment of pain outcomes and implications for inclusion criteria William D. Chey, MD Professor of Medicine University of Michigan What is the Irritable Bowel Syndrome Symptom based
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More informationEmerging Treatments for IBS-C and Clinical Trial Endpoints
Emerging Treatments for IBS-C and Clinical Trial Endpoints Lin Chang, M.D. Oppenheimer Family Center for Neurobiology of Stress David Geffen School of Medicine at UCLA Learning Objectives Describe current
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 7 Last Review Date: November 30, 2018 Opioid Antagonist
More informationAging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS OVERVIEW
Aging Persons with Intellectual Developmental Disorders (IDD): Constipation KEYPOINTS A major medical conditions that commonly is seen among persons with IDD and may lead to serious complications is constipation.
More informationClass Review: Drugs for Constipation
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHorizon Scanning Technology Summary. Methylnaltrexone for opioid induced constipation in advanced illness and palliative care
Horizon Scanning Technology Summary National Horizon Scanning Centre Methylnaltrexone for opioid induced constipation in advanced illness and palliative care April 2007 This technology summary is based
More informationHorizon Scanning Technology Briefing. Alvimopan (Entrareg ) for opioid-induced bowel disfunction. National Horizon Scanning Centre.
Horizon Scanning Technology Briefing National Horizon Scanning Centre Alvimopan (Entrareg ) for opioid-induced bowel disfunction August 2006 This technology briefing is based on information available at
More informationOIC, opioid-induced constipation.
Disclosures Charles E. Argoff, MD Speakers Bureau for Allergan, Inc., AstraZeneca plc, Depomed, Inc., Iroko Pharmaceuticals LLC, Janssen Pharmaceuticals, Inc., Millenium Laboratories, and Xenoport Inc.
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide), Symproic (naldemedine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 5 Last Review Date: June 22, 2017 Opioid Antagonist
More informationDrug Evaluation. Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction
Use of lubiprostone in constipating disorders and its potential for opioid-induced bowel dysfunction Lubiprostone is a novel medication, approved by the US FDA for the treatment of chronic idiopathic constipation
More informationOpioid constipation treatment dulcolax
P ford residence southampton, ny Opioid constipation treatment dulcolax Posts about how to relieve constipation instantly written by gbrese1958. Official Web site for MOVANTIK (naloxegol) tablets, for
More informationAdvances in Palliative Care
Steven Pantilat, MD Professor of Clinical Medicine Alan M. Kates and John M. Burnard Endowed Chair in Palliative Care Director, Palliative Care Program and Palliative Care Leadership Center Division of
More informationMovantik (naloxegol), Relistor (methylnaltrexone bromide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.06 Subject: Opioid Antagonist Drug Class Page: 1 of 5 Last Review Date: December 2, 2016 Opioid Antagonist
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationApplying Quality to Postsurgical Opioid-Induced Constipation
Applying Quality to Postsurgical Opioid-Induced Constipation Applying Quality to Postsurgical Opioid-Induced Constipation Ernest J. Dole, PharmD, PhC, FASHP, BCPS Clinical Pharmacist University of New
More informationEvidence-based Treatment Strategies for
Evidence-based Treatment Strategies for Chronic Constipation William D. Chey, MD Professor of Medicine University of Michigan Rome III criteria*: Chronic constipation Must include 2 of the following (>25%
More informationOIC. Drug List. Personalized Approach to Opioid induced Constipation. Learning Objectives. Presenter Disclosure Information. Management Options
1:30 2:45 pm Personalized Approach to OIC: Improving Communication and Managing Treatment SPEAKER Jeffrey A. Gudin, MD Presenter Disclosure Information The following relationships exist related to this
More informationChapter 31 Bowel Elimination
Chapter 31 Bowel Elimination Defecation Defecation: the act of expelling feces from the body Peristalsis: rhythmic contractions of intestinal smooth muscle to facilitate defecation Gastrocolic reflex:
More informationSlide #43. Functional Disorders - An Update 11/8/ MA ACP Annual Scientific Meeting. Functional Disorders: An Update
Functional Disorders: An Update Anthony Lembo, M.D. Associate Professor of Medicine Beth Israel Deaconess Medical Center Harvard Medical School Boston, MA Disclosure of Financial Relationships Anthony
More informationDOCTOR DISCUSSION GUIDE
What your doctor needs to know To make your appointment more productive, share this completed guide with your doctor. That way, he or she can recommend an appropriate treatment plan for you. Check the
More informationEpisode 3.2 Show Notes Constipation
Episode 3.2 Show Notes Constipation Presented by: Dr Jo Preston, Dr Iain Wilkinson & Mairéad O Malley Faculty: Clare Watson, Wendy Grosvenor Guest faculty: Dr Gaggandeep Singh Alg Broadcast Date: 28th
More informationOpioid-Induced Constipation: Considerations for Formulary Decision Makers
Continuing Education Opioid-Induced Constipation: Considerations for Formulary Decision Makers Faculty Steven R. Peskin, MD, MBA, FACP Associate Clinical Professor of Medicine Robert Wood Johnson School
More informationCurrent Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation
Current Pharmacological Treatment Options in Chronic Constipation and IBS with Constipation Anthony Lembo, M.D. Associate Professor of Medicine Harvard Medical School Director, GI Motility Center Beth
More informationDaniel Canafax, PharmD VP, Clinical Research Theravance, Inc.
Demonstrates Improvement in Bowel Movement Frequency and Bristol Stool Scores in a Phase 2b Study of Patients with Opioid-Induced Constipation (OIC) Ross Vickery, PhD, 1 Yu-Ping Li, PhD, 1 Ullrich Schwertschlag,
More informationScandinavian Journal of Pain
Scandinavian Journal of Pain 11 (2016) 111 122 Contents lists available at ScienceDirect Scandinavian Journal of Pain journal homepage: www.scandinavianjournalpain.com Topical review Definition, diagnosis
More informationDisclosures. Objectives. Pre-Test Question 1. Pre-Test Question 2. Pre-Test Question 3 9/23/2016
Disclosures Beating the Bowel Blues: An Update on the Treatment of Irritable Bowel Syndrome Matthew Nelson, PharmDBCPS, Roosevelt University College of Pharmacy Matthew Nelson declares no conflicts of
More informationMANAGING CONSTIPATION
MANAGING CONSTIPATION INFORMATION FOR OLDER ADULTS, FAMILIES, AND CAREGIVERS READ THIS PAMPHLET TO LEARN: What Constipation is. The Symptoms of Constipation. How to Help Manage Constipation. WHAT IS CONSTIPATION?
More informationMANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES
Enrique Rey Professor of Medicine Head. Department of Digestive Diseases Hospital Clínico San Carlos Complutense University Madrid, Spain MANAGEMENT OF CHRONIC CONSTIPATION BEYOND LAXATIVES CONSTIPATION:
More informationCONSTIPATION. Atan Baas Sinuhaji
CONSTIPATION Atan Baas Sinuhaji Sub Division of Pediatrics Gastroentero-Hepatolgy Department of ChildHealth,School of Medicine University of Sumatera Utara MEDAN DEFECATION REGULAR PATTERN CONSTIPATION
More informationManaging constipation in residential care
Managing constipation in residential care Amanda Lee Lecturer, Hull University ; PhD Candidate, Gastroesophageal cancers Key Points Constipation is a major problem in residential care Early detection and
More informationTreatment of Constipation in Adults
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330407 Treatment of Constipation in Adults Use this document as a stepwise
More informationChildhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands
Childhood constipation, a real problem..? Marc Benninga, Emma Children s Hospital, AMC, Amsterdam, the Netherlands Constipation 0-10% >10-20% >20-30% >30-40% Mugie SM, et al. Best Pract & Res Clin Gastroenterol
More informationProtocol to support reducing the use of and the effective use of laxatives. HaRD CCG employed Pharmacists and Medicines Optimisation Technicians.
NY&AWC Medicines Management Team Protocol to support reducing the use of and the effective use of laxatives Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols
More informationScoop on the poop: Constipation in the Elderly
Scoop on the poop: Constipation in the Elderly Laurie Archbald-Pannone, MD, MPH Assistant Professor Division of General Medicine, Geriatrics, & Palliative Care Division of Infectious Diseases and International
More informationLOTRONEX and its authorized generic alosetron hydrochloride:
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The Prescribing Program for LOTRONEX TM Prescriber Education Slide Deck PROMETHEUS and the Link Design
More informationSynergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation
January 19, 2017 Synergy Pharmaceuticals TRULANCE (Plecanatide) Receives U.S. FDA Approval for the Treatment of Adults with Chronic Idiopathic Constipation NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals
More informationOpioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital
Opioid Induced Constipation Lisa Clince Acute Pain CNS Palmerston North Hospital 21-04-2016 MidCentral District Health Board 1 Overview Patient Experience Opioid Collaborative Constipation defined Opioid
More informationOpioid induced constipation in cancer patients: pathophysiology, diagnosis and treatment
Expert Review of Quality of Life in Cancer Care ISSN: (Print) 2380-9000 (Online) Journal homepage: http://www.tandfonline.com/loi/terq20 Opioid induced constipation in cancer patients: pathophysiology,
More informationOpioid-induced constipation a preventable problem
www.veteransmates.net.au Opioid-induced a preventable problem One of the most common adverse effects of chronic opioid therapy is. 1-4 Up to 95% of patients prescribed an opioid report as a side effect,
More informationI ve had it with you and your emotional constipation.
I ve had it with you and your emotional constipation. Washington Irving If Mother had to be told not to put the entire brick of ivory up Junior s hindquarters, constipation is the least of his problems.
More informationIRONWOOD AND FOREST ANNOUNCE POSITIVE LINACLOTIDE RESULTS FROM PHASE 3 TRIAL IN PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION
FOR IMMEDIATE RELEASE Ironwood Contact: Forest Contact: Susan Brady Frank J. Murdolo Corporate Communications Vice President, Investor Relations 617.621.8304 212.224.6714 sbrady@ironwoodpharma.com frank.murdolo@frx.com
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationCommon Gastrointestinal Problems in the Elderly
Common Gastrointestinal Problems in the Elderly Brian Viviano, D.O. Objectives Understand the pathophysiology, clinical manifestations, diagnosis and management of GI diseases of the elderly. Differentiate
More informationAMITIZA (lubiprostone) capsules, for oral use Initial U.S. Approval: 2006
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMITIZA safely and effectively. See full prescribing information for AMITIZA. AMITIZA (lubiprostone)
More informationEffective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1
Effective pain management begins with OFIRMEV (acetaminophen) injection FIRST Proven efficacy with rapid reduction in pain 1 Fast onset of pain relief with 7% reduction in visual analog scale (VAS) scores
More informationAdvancing gastroenterology, improving patient care
American College of Gastroenterology Advancing gastroenterology, improving patient care Note to Visitors: A fully updated ACG Systematic Review on the Management of Chronic Idiopathic Constipation and
More informationWARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
June 5, 2018 Synergy Pharmaceuticals Highlights New Data at Digestive Disease Week (DDW) 2018 Linking Uroguanylin Deficiency to Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome with Constipation
More informationTreatment Conversation Guide
Created For: Doctor Appointment Date: Treatment Conversation Guide What your healthcare provider needs to know How does your condition affect your life? To make your appointment more productive, fill out
More informationDisorders in which symptoms cannot be explained by the presence of structural or tissue abnormalities Irritable bowel syndrome Functional heartburn Functional dyspepsia Functional constipation Functional
More informationUnderstanding the Prevalence and Impact of Constipation in Canada. A Special Report from the Canadian Digestive Health Foundation
Understanding the Prevalence and Impact of Constipation in Canada A Special Report from the Canadian Digestive Health Foundation February 2014 Understanding the Prevalence and Impact of Constipation in
More informationConstipation: pathophysiology and management
REVIEW C URRENT OPINION Constipation: pathophysiology and management Arnold Wald Purpose of review Continuing advances in pharmaceutical development are providing an expanding array of treatment approaches
More informationCHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University
CHAPTER 11 Functional Gastrointestinal Disorders (FGID) Mr. Ashok Kumar Dept of Pharmacy Practice SRM College of Pharmacy SRM University 1 Definition of FGID Chronic and recurrent symptoms of the gastrointestinal
More informationSummary of the risk management plan (RMP) for Moventig (naloxegol)
EMA/611606/2014 Summary of the risk management plan (RMP) for Moventig (naloxegol) This is a summary of the risk management plan (RMP) for Moventig, which details the measures to be taken in order to ensure
More informationOST. Pharmacology & Therapeutics. Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO
OST Pharmacology & Therapeutics Leo O. Lanoie, MD, MPH, FCFP, CCSAM, ABAM, MRO Disclaimer In the past two years I have received no payment for services from any agency other than government or academic.
More informationChronic constipation affects up to 63
CHRONICALLY QUESTIONED ABOUT CHRONIC CONSTIPATION?* Anthony J. Lembo, MD ABSTRACT Chronic constipation is a common condition that affects more American adults than hypertension, migraine, diabetes, asthma,
More informationDavid Leff, DO. April 13, Disclosure. I have the following financial relationships to disclosure:
David Leff, DO AOMA 94 th Annual Convention April 13, 2016 Disclosure I have the following financial relationships to disclosure: Speaker s Bureau: Allergan Labs, Takeda Pharmaceutical, Valeant Pharmaceutical
More informationMOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l
MOVICOL -Half Powder for Solution (macrogol 3350) Product Name: Product Description: MOVICOL-Half Each sachet of MOVICOL-Half contains: Macrogol 3350 6.563 g Sodium chloride 175.4 mg Sodium bicarbonate
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationMOVICOL Junior Powder for Solution (macrogol 3350)
MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride
More informationProf. Dr. Mufti Munsurar Rahman Dept. of Medicine Enam Medical College Hospital
Prof. Dr. Mufti Munsurar Rahman Dept. of Medicine Enam Medical College Hospital Functional constipation : prevalence and life style factors in a district of Bangladesh Perveen I, Rahman MM, Saha M, Parvin
More information